PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

New lead against HIV could finally hobble the virus's edge

2015-03-19
(Press-News.org) DENVER, March 23, 2015 -- Since HIV emerged in the '80s, drug "cocktails" transformed the deadly disease into a manageable one. But the virus is adept at developing resistance to drugs, and treatment regimens require tweaking that can be costly. Now scientists at the 249th National Meeting & Exposition of the American Chemical Society (ACS) are announcing new progress toward affordable drugs that could potentially thwart the virus's ability to resist them.

ACS, the world's largest scientific society, is holding the meeting here through Thursday. It features nearly 11,000 presentations.

"This disease has gone on for over three decades," says Dennis Liotta, Ph.D. "We've got to try to find new solutions. Even with the 30 approved drugs that we have, and even when you completely suppress viral replication, we still see disease progression."

So Liotta's team at Emory University decided to tackle a seemingly intractable problem that had been plaguing efforts to defeat the virus.

To replicate, Liotta explains, HIV fuses with human immune cells by interacting with key proteins. Its genetic contents subsequently spill inside the immune cells, and the viral proteins then hijack the cellular machinery to make copies of themselves.

One drug company (Pfizer) has developed a compound that blocks HIV's interaction with one of those proteins, a co-receptor called CCR5. But the virus can also use a second co-receptor, CXCR4, to enter cells. If a drug targets just CCR5, a more virulent strain that favors CXCR4 could emerge over time, says Liotta.

In theory, drugs targeting CXCR4 would be an effective addition to the arsenal against HIV. But interfering with that protein, which regulates several of the body's inflammatory responses, could lead to serious side effects.

"With a chronic infection like HIV, it's very challenging to take a drug every day of your life if you have significant side effects," Liotta says. "This is a very high bar. No drug that functions as a CXCR4 antagonist for HIV has gotten over that bar."

Liotta's team decided to search for compounds that might be able to bind both CCR5 and CXCR4 at the same time, while avoiding serious side effects.

"Essentially, we took a step back and said instead of creating yet another cocktail of multiple drugs to stop the different mechanisms of HIV, we thought we could design one that hit multiple targets at once," says Anthony Prosser, a graduate student in Liotta's lab. If a new drug could block HIV entry by interfering with CCR5 and CXCR4, it could be paired with a traditional cocktail targeting other stages of the virus lifecycle for an even more robust treatment.

Prosser came up with a simple, inexpensive method to synthesize compounds that likely would bind both co-receptors. Lab tests identified the most effective ones, and the group's partners at pharmaceutical company Bristol-Myers Squibb found that the compounds also blocked HIV reverse transcriptase, an enzyme that's key to the virus's ability to copy itself.

"The agents were active against CCR5, CXCR4 and HIV reverse transcriptase," Liotta says. "That was unprecedented. Also, they don't perturb any of the CXCR4 signaling pathways that lead to inflammation."

An additional benefit of this approach is that the compounds target proteins on human cells. Most HIV drugs target viral proteins, but because they often mutate when exposed to antiretroviral agents, resistance can develop quickly. When that happens, patients have to switch to a new drug combination that can be less effective than the previous treatment. Human proteins rarely mutate to a significant extent, so HIV will be far less likely get around drug combination therapies that include a CXCR4/CCR5 inhibitor, Liotta explains. Since these agents are inexpensive to prepare, they could potentially keep treatment affordable for millions, particularly in the developing world.

Now the lab is working to further control the activity of these compounds, boost their potency and minimize their potential toxicity.

"We've got a long way to go, but this is a very exciting finding," Liotta says.

INFORMATION:

A press conference on this topic will be held Monday, March 23, at 3 p.m. Mountain time in the Colorado Convention Center. Reporters may check-in at Room 104 in person, or watch live on YouTube http://bit.ly/ACSLiveDenver. To ask questions, sign in with a Google account.

The work was funded by Liotta's earlier work on HIV drug emtricitabine that resulted in a sale by Emory University to Gilead Sciences.

The American Chemical Society is a nonprofit organization chartered by the U.S. Congress. With more than 158,000 members, ACS is the world's largest scientific society and a global leader in providing access to chemistry-related research through its multiple databases, peer-reviewed journals and scientific conferences. Its main offices are in Washington, D.C., and Columbus, Ohio.

To automatically receive news releases from the American Chemical Society, contact newsroom@acs.org.

Note to journalists: Please report that this research is being presented at a meeting of the American Chemical Society.

Follow us: Twitter | Facebook

Title Discovery and synthesis of first-generation single-drug "cocktails" to combat HIV

Abstract Current HIV regimens require at least three antiviral drugs to arrest ongoing viral replication and restore immune function. Unfortunately, these so-called "drug cocktails" come with significant financial burden, a continually emerging set of long term side effects, and the potential for resistance if not taken as prescribed. Resistance develops due to the plasticity of the viral genome which is able to produce several isoforms of the protein that are targeted by antiretroviral therapy. Thus, it would be advantageous to target specific host proteins which exist as a single isoform and are not significantly responsive to selective pressures. Of particular interest are the chemokines CCR5 and CXCR4, which are required for HIV cellular entry. Unfortunately, inhibition of CCR5 facilitates viral evolution toward CXCR4 entry and vice versa. Therefore, it is necessary to inhibit both chemokines simultaneously to completely blockade HIV. We have discovered and synthesized a novel series of small molecules that demonstrate potent anti-HIV activity against both R5 and X4 tropic viral strains that specifically bind both co-receptors at once with minimal impact on cellular signaling. Additionally these molecules have been shown serendipitously to be potent inhibitors of HIV reverse transcriptase. These three complementary methods of action may yield a single drug therapy for HIV. The discovery, synthesis, SAR, and unique biological profile for these molecules will be discussed.

Due to a premature posting of this release, the embargo is now lifted as of March 19. END



ELSE PRESS RELEASES FROM THIS DATE:

Ocean pipes 'not cool,' would end up warming climate

2015-03-19
Washington, D.C.--To combat global climate change caused by greenhouse gases, alternative energy sources and other types of environmental recourse actions are needed. There are a variety of proposals that involve using vertical ocean pipes to move seawater to the surface from the depths in order to reap different potential climate benefits. A new study from a group of Carnegie scientists determines that these types of pipes could actually increase global warming quite drastically. It is published in Environmental Research Letters. One proposed strategy--called Ocean ...

Altering brain chemistry makes us more sensitive to inequality

2015-03-19
What if there were a pill that made you more compassionate and more likely to give spare change to someone less fortunate? UC Berkeley scientists have taken a big step in that direction. A new study by UC Berkeley and UC San Francisco researchers finds that giving a drug that changes the neurochemical balance in the prefrontal cortex of the brain causes a greater willingness to engage in prosocial behaviors, such as ensuring that resources are divided more equally. The researchers also say that future research may lead to a better understanding of the interaction between ...

Better season-long nutrient supply in soybean a 'low-hanging fruit' to improve upon

2015-03-19
URBANA, Ill. - Over the last several decades there have been substantial yield improvements in soybean. Because of new varieties and new agronomic practices, the yield potential in soybean is higher now than ever before. But a lack of updated information on the nutritional needs of soybean crops may be limiting the crop's potential. Researchers from the University of Illinois Crop Physiology Laboratory led by Fred Below have recently provided an updated set of nutrition needs for soybean, identifying exactly which nutrients the plant needs, when those nutrients are accumulated ...

Spot treatment

Spot treatment
2015-03-19
Acne, a scourge of adolescence, may be about to meet its ultra high-tech match. By using a combination of ultrasound, gold-covered particles and lasers, researchers from UC Santa Barbara and the private medical device company Sebacia have developed a targeted therapy that could potentially lessen the frequency and intensity of breakouts, relieving acne sufferers the discomfort and stress of dealing with severe and recurring pimples. "Through this unique collaboration, we have essentially established the foundation of a novel therapy," said Samir Mitragotri, professor ...

Our eyes multi-task even when we don't want them to, researchers find

2015-03-19
Our eyes are drawn to several dimensions of an object--such as color, texture, and luminance--even when we need to focus on only one of them, researchers at New York University and the University of Pennsylvania have found. The study, which appears in the journal Current Biology, points to the ability of our visual system to integrate multiple components of an item while underscoring the difficulty we have in focusing on a particular aspect of it. "Even when we want and need to focus on one dimension of things we come across every day, such as the texture of your cat's ...

New technologies for getting the most out of semen

2015-03-19
For in vitro fertilization and other assisted reproductive technologies, selecting the healthiest and best swimming sperm from a sample of semen can dramatically increase success. Microfluidics--micro-scale technologies that were originally developed to enable high-throughput gene sequencing and for Point-Of-Care diagnostics--are now being adapted to enhance sperm sorting. These new methods, reviewed by engineers in the journal Trends in Biotechnology, are generating promising results in applications such as single-sperm genomics, in-home male fertility testing, and wildlife ...

First stem cell-based approach to treat type 2 diabetes effective in mice

First stem cell-based approach to treat type 2 diabetes effective in mice
2015-03-19
A combination of human stem cell transplantation and antidiabetic drugs proved to be highly effective at improving body weight and glucose metabolism in a mouse model of type 2 diabetes. The findings, published March 19th by Stem Cell Reports, could set the stage for clinical trials to test the first stem cell-based approach for insulin replacement in patients with type 2 diabetes. Type 2 diabetes, which accounts for 90%-95% of the now approaching 400 million cases of diabetes worldwide, is currently treated by oral medication, insulin injections, or both to control blood ...

Vitamin D helps immune cells prevent atherosclerosis and diabetes

2015-03-19
Altered signaling through the vitamin D receptor on certain immune cells may play a role in causing the chronic inflammation that leads to cardiometabolic disease, the combination of type 2 diabetes and heart disease that is the most common cause of illness and death in Western populations. The research appears March 19 in the journal Cell Reports. "Because low vitamin D levels are associated with diabetes and heart disease, we looked at the connections between vitamin D, immune function, and these disease states," says senior author Carlos Bernal-Mizrachi, of the Washington ...

Stem cells show promise for reversing type 2 diabetes

Stem cells show promise for reversing type 2 diabetes
2015-03-19
Scientists at the University of British Columbia and BetaLogics, part of Janssen Research & Development, LLC have shown for the first time that Type 2 diabetes can be effectively treated with a combination of specially-cultured stem cells and conventional diabetes drugs. Stem cells - generic cells that haven't yet taken on specialized form and function - have recently been used by scientists at UBC and elsewhere to reverse Type 1 diabetes in mice. In Type 1 diabetes, which usually begins in childhood, the pancreas produces little or no insulin, the hormone that enables ...

UCSF team finds key to making neurons from stem cells

2015-03-19
A research team at UC San Francisco has discovered an RNA molecule called Pnky that can be manipulated to increase the production of neurons from neural stem cells. The research, led by neurosurgeon Daniel A. Lim, MD, PhD, and published on March 19, 2015 in Cell Stem Cell, has possible applications in regenerative medicine, including treatments of such disorders as Alzheimer's disease, Parkinson's disease and traumatic brain injury, and in cancer treatment. Pnky is one of a number of newly discovered long noncoding RNAs (lncRNAs), which are stretches of 200 or more ...

LAST 30 PRESS RELEASES:

Signs identified that precede sudden arrhythmic death syndrome in young people

Discovery of bacteria's defence against viruses becomes a piece of the puzzle against resistance

Pre-eclampsia is associated with earlier onset and higher incidence of cardiovascular risk factors

Warwick astronomers discover doomed pair of spiralling stars on our cosmic doorstep

Soil conditions significantly increase rainfall in world’s megastorm hotspots

NK cells complexed with bispecific antibody yield high response rates in patients with lymphoma

Planetary health diet and mediterranean diet associated with similar survival and sustainability benefits

Singapore launches national standard to validate antimicrobial disinfectant products

Molecular stool test could improve detection of tuberculosis in adults with HIV

Suspected fibrocartilaginous embolus in Asian small-clawed otter (Aonyx cinereus)

Enhancing heat transfer using the turbulent flow of viscoelastic fluids

Exercise as an anti-ageing intervention to avoid detrimental impact of mental fatigue

UMass Amherst Nursing Professor Emerita honored as ‘Living Legend’

New guidelines aim to improve cystic fibrosis screening

Picky eaters by day, buffet by night: Butterfly, moth diets sync to plant aromas

Pennington Biomedical’s Dr. Leanne Redman honored with the E. V. McCollum Award from the American Society for Nutrition

CCNY physicists uncover electronic interactions mediated via spin waves

Researchers’ 3D-printing formula may transform future of foam

Nurture more important than nature for robotic hand

Drug-delivering aptamers target leukemia stem cells for one-two knockout punch

New study finds that over 95% of sponsored influencer posts on Twitter were not disclosed

New sea grant report helps great lakes fish farmers navigate aquaculture regulations

Strain “trick” improves perovskite solar cells’ efficiency

How GPS helps older drivers stay on the roads

Estrogen and progesterone stimulate the body to make opioids

Dancing with the cells – how acoustically levitating a diamond led to a breakthrough in biotech automation

Machine learning helps construct an evolutionary timeline of bacteria

Cellular regulator of mRNA vaccine revealed... offering new therapeutic options

Animal behavioral diversity at risk in the face of declining biodiversity

Finding their way: GPS ignites independence in older adult drivers

[Press-News.org] New lead against HIV could finally hobble the virus's edge